Rgenta Therapeutics scores $20m seed
Cambridge, Massachusetts-based Rgenta Therapeutics, a developer of RNA-targeting medicines, has secured $20 million in seed funding.
Cambridge, Massachusetts-based Rgenta Therapeutics, a developer of RNA-targeting medicines, has secured $20 million in seed funding.